Pavilion Clinical Trial
Patients with Diabetic Retinopathy (closed for recruitment)
The purpose of this study is to investigate the effects and safety of the Port Delivery System (PDS) in patients with Diabetic Retinopathy. The PDS is an investigational drug delivery technology that allows physicians to continuously treat the eye with medication rather than frequent intravitreal injections.
Nonproliferative Diabetic Retinopathy (NPDR) is a leading cause of vision loss in patients with diabetes. NPDR occurs when the blood vessels within the retina (a tissue t the back of the eye) start to leak or bleed causing vision to be blurred and distorted. The retina is located at the back of the eye and controls central vision.
All participants will receive either Ranibizumab injections or the investigational Port Delivery System with Ranibizumab. No one will receive a placebo. Review more details on this study at ClinicalTrials.gov.